原发性结膜滤泡性淋巴瘤复发时病灶内注射利妥昔单抗。
Intralesional rituximab in primary conjunctival follicular lymphoma relapsed.
作者信息
Rodríguez Villa S, Ruiz Rodríguez M J, Vargas Pabón M
机构信息
Servicio de Oftalmología, Hospital Universitario de Cabueñes, Gijón, Asturias, España.
Servicio de Oftalmología, Hospital Comarcal Jarrio, Coaña, Asturias, España.
出版信息
Arch Soc Esp Oftalmol. 2017 Jul;92(7):326-329. doi: 10.1016/j.oftal.2016.11.004. Epub 2016 Dec 13.
CLINICAL CASE
A 49-year-old woman experienced a local relapse of a primary follicular lymphoma (FL) of the conjunctiva. She received 4 weekly intra-lesional injections followed by 6 monthly injections of rituximab (6mg/ml). A clinical response was achieved after first injection. No adverse ocular event or signs of lymphoma relapse were seen after 10 months of follow-up.
DISCUSSION
Intralesional administration of rituximab for treating primary FL of the conjunctiva was an effective and safe therapeutic option; therefore it could be an alternative to other conventional treatments, such as radiotherapy or chemotherapy.
临床病例
一名49岁女性原发性结膜滤泡性淋巴瘤出现局部复发。她接受了4次每周一次的病灶内注射，随后每月注射6次利妥昔单抗（6mg/ml）。首次注射后即取得临床缓解。随访10个月后未见眼部不良事件或淋巴瘤复发迹象。
讨论
病灶内注射利妥昔单抗治疗原发性结膜滤泡性淋巴瘤是一种有效且安全的治疗选择；因此，它可作为放疗或化疗等其他传统治疗方法的替代方案。
Zotero 插件